Sorrento, a biopharmaceutical company, completed its acquisition of SmartPharm, a gene-encoded protein therapeutics company. Financial terms were not disclosed. "We are very encouraged by the preclinical data generated thus far by our STI-2020dna plasmid candidate against Covid-19. But beyond STI-2020dna the integration of the plasmid DNA technology with our existing antibody products has the potential to make antibody therapy much more accessible and affordable for patients, and is applicable to a multitude of indications ranging from cancer to infectious diseases," Henry Ji, Sorrento CEO.